Exact Mass: 367.189582
Exact Mass Matches: 367.189582
Found 500 metabolites which its exact mass value is equals to given mass value 367.189582,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Propiverine
Propiverine is an anticholinergic drug used for the treatment of urinary urgency, frequency and urge incontinence, all symptoms of overactive bladder syndrome. A modified release preparation is also available, taken once daily. G - Genito urinary system and sex hormones > G04 - Urologicals > G04B - Urologicals > G04BD - Drugs for urinary frequency and incontinence C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D010276 - Parasympatholytics D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists C78272 - Agent Affecting Nervous System > C29698 - Antispasmodic Agent D000089162 - Genitourinary Agents > D064804 - Urological Agents
6-hydroxytryprostatin B
A cyclic dipeptide that is brevianamide F (cyclo-L-Trp-L-Pro) substituted at positions 2 and 6 on the indole ring by prenyl and hydroxy groups respectively.
Bambuterol
C18H29N3O5 (367.21071040000004)
Bambuterol is only found in individuals that have used or taken this drug. It is a long acting beta-adrenoceptor agonist used in the treatment of asthma. It is a prodrug of terbutaline.The pharmacologic effects of bambuterol are at least in part attributable to stimulation through beta-adrenergic receptors (beta 2 receptors) of intracellular adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic AMP. Increased cyclic AMP levels are associated with relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells. R - Respiratory system > R03 - Drugs for obstructive airway diseases > R03C - Adrenergics for systemic use > R03CC - Selective beta-2-adrenoreceptor agonists D019141 - Respiratory System Agents > D018927 - Anti-Asthmatic Agents > D001993 - Bronchodilator Agents C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C87053 - Adrenergic Agonist D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents
Piperundecalidine
Piperundecalidine is found in herbs and spices. Piperundecalidine is an alkaloid from the fruits of Piper longum (long pepper
Tryptophyl-Tyrosine
C20H21N3O4 (367.15319860000005)
Tryptophyl-Tyrosine is a dipeptide composed of tryptophan and tyrosine. It is an incomplete breakdown product of protein digestion or protein catabolism. Some dipeptides are known to have physiological or cell-signaling effects although most are simply short-lived intermediates on their way to specific amino acid degradation pathways following further proteolysis. This dipeptide has not yet been identified in human tissues or biofluids and so it is classified as an Expected metabolite.
Casuarine 6-alpha-D-glucoside
Casuarine 6-alpha-D-glucoside is found in fruits. Casuarine 6-alpha-D-glucoside is an alkaloid from Eugenia jambolana (jambolan
Tyrosyl-Tryptophan
C20H21N3O4 (367.15319860000005)
Tyrosyl-Tryptophan is a dipeptide composed of tyrosine and tryptophan. It is an incomplete breakdown product of protein digestion or protein catabolism. Some dipeptides are known to have physiological or cell-signaling effects although most are simply short-lived intermediates on their way to specific amino acid degradation pathways following further proteolysis. This dipeptide has not yet been identified in human tissues or biofluids and so it is classified as an Expected metabolite.
N-Acetyl-6-O-L-fucosyl-D-glucosamine
N-Acetyl-6-O-L-fucosyl-D-glucosamine is an oligosaccharin obtained from human milk (Fiziologiya i Biokhimiya Kulturnykh Rastenii (2002), 34(1), 52-57) [HMDB] N-Acetyl-6-O-L-fucosyl-D-glucosamine is an oligosaccharin obtained from human milk (Fiziologiya i Biokhimiya Kulturnykh Rastenii (2002), 34(1), 52-57).
2-Acetamido-2-deoxy-6-O-a-L-fucopyranosyl-D-glucose
2-Acetamido-2-deoxy-6-O-a-L-fucopyranosyl-D-glucose is an oligosaccharide isolated from the urine of patients with fucosidosis (Fucosidosis is an autosomal recessive lysosomal storage disease caused by defective alpha-L-fucosidase with accumulation of fucose in the tissues. Different phenotypes include clinical features such as neurologic deterioration, growth retardation, visceromegaly, and seizures in a severe early form; coarse facial features, angiokeratoma corporis diffusum, spasticity and delayed psychomotor development in a longer surviving form; and an unusual spondylometaphyseoepiphyseal dysplasia in yet another form. OMIM 230000). (PMID 728478) [HMDB] 2-Acetamido-2-deoxy-6-O-a-L-fucopyranosyl-D-glucose is an oligosaccharide isolated from the urine of patients with fucosidosis (Fucosidosis is an autosomal recessive lysosomal storage disease caused by defective alpha-L-fucosidase with accumulation of fucose in the tissues. Different phenotypes include clinical features such as neurologic deterioration, growth retardation, visceromegaly, and seizures in a severe early form; coarse facial features, angiokeratoma corporis diffusum, spasticity and delayed psychomotor development in a longer surviving form; and an unusual spondylometaphyseoepiphyseal dysplasia in yet another form. OMIM 230000). (PMID 728478).
3-O-fucopyranosyl-2-acetamido-2-deoxyglucopyranose
3-O-fucopyranosyl-2-acetamido-2-deoxyglucopyranose is an oligosaccharide is a fucosylated oligosaccharide specific to human, and in milk forms part of the innate immune system. (PMID: 1579031). It is present in a number of proteins, such as human transferrin. Hepatocytes contain a receptor that binds glycoproteins specifically through the fucose in alpha13 linkage to N-acetylglucosamine. (PMID: 276862). It is also present in some forms of human kidney enzyme alpha-L-fucosidase (EC 3.2.1.51) (PMID: 7215135). 3-O-fucopyranosyl-2-acetamido-2-deoxyglucopyranose is an oligosaccharide is a fucosylated oligosaccharide specific to human, and in milk forms part of the innate immune system. (PMID: 1579031)
Desmethylazelastine
C21H22ClN3O (367.14513120000004)
Desmethylazelastine is a metabolite of Azelastine. Azelastine, an antiallergy and antiasthmatic drug, has been reported to be mainly N-demethylated to desmethylazelastine in humans. Azelastine N-demethylation in humans liver microsomes is catalyzed mainly by CYP3A4 and CYP2D6, and CYP1A2 to a small extent (in average, 76.6, 21.8, and 3.9\\%, respectively. (PMID: 10570018)
Dodeca-6,8,10-trienedioylcarnitine
C19H29NO6 (367.19947740000003)
Dodeca-6,8,10-trienedioylcarnitine is an acylcarnitine. More specifically, it is an dodeca-6,8,10-trienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Dodeca-6,8,10-trienedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine Dodeca-6,8,10-trienedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
Dodeca-4,7,10-trienedioylcarnitine
C19H29NO6 (367.19947740000003)
Dodeca-4,7,10-trienedioylcarnitine is an acylcarnitine. More specifically, it is an dodeca-4,7,10-trienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Dodeca-4,7,10-trienedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine Dodeca-4,7,10-trienedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(2E,6E,8E)-Dodeca-2,6,8-trienedioylcarnitine
C19H29NO6 (367.19947740000003)
(2E,6E,8E)-Dodeca-2,6,8-trienedioylcarnitine is an acylcarnitine. More specifically, it is an (2E,6E,8E)-dodeca-2,6,8-trienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (2E,6E,8E)-Dodeca-2,6,8-trienedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (2E,6E,8E)-Dodeca-2,6,8-trienedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
Dodeca-5,7,9-trienedioylcarnitine
C19H29NO6 (367.19947740000003)
Dodeca-5,7,9-trienedioylcarnitine is an acylcarnitine. More specifically, it is an dodeca-5,7,9-trienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Dodeca-5,7,9-trienedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine Dodeca-5,7,9-trienedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
Dodeca-4,6,8-trienedioylcarnitine
C19H29NO6 (367.19947740000003)
Dodeca-4,6,8-trienedioylcarnitine is an acylcarnitine. More specifically, it is an dodeca-4,6,8-trienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Dodeca-4,6,8-trienedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine Dodeca-4,6,8-trienedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
Dodeca-3,6,9-trienedioylcarnitine
C19H29NO6 (367.19947740000003)
Dodeca-3,6,9-trienedioylcarnitine is an acylcarnitine. More specifically, it is an dodeca-3,6,9-trienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Dodeca-3,6,9-trienedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine Dodeca-3,6,9-trienedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
3-(3-Methyl-5-pentylfuran-2-yl)propanoylcarnitine
C20H33NO5 (367.23586080000007)
3-(3-methyl-5-pentylfuran-2-yl)propanoylcarnitine is an acylcarnitine. More specifically, it is an 3-(3-methyl-5-pentylfuran-2-yl)propanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-(3-methyl-5-pentylfuran-2-yl)propanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 3-(3-methyl-5-pentylfuran-2-yl)propanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
N-Acetyl-S-trans,trans-farnesyl-L-cysteine
C20H33NO3S (367.2181028000001)
{4-[4-(6-Carbamoyl-3,5-dimethylpyrazin-2-yl)phenyl]cyclohexyl}acetic acid
AZD7687 is a potent, selective, reversible and orally active diacylglycerol acyltransferase 1 (DGAT1) inhibitor with an IC50 of 80 nM for human DGAT1. AZD7687 can be used for type 2 diabetes mellitus and obesity research[1][2].
Corynoline
C21H21NO5 (367.14196560000005)
Fradafiban
C20H21N3O4 (367.15319860000005)
Phenoperidine
D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D009294 - Narcotics N - Nervous system > N01 - Anesthetics > N01A - Anesthetics, general > N01AH - Opioid anesthetics D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent D002491 - Central Nervous System Agents > D000700 - Analgesics
Prucalopride
D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D017366 - Serotonin Receptor Agonists A - Alimentary tract and metabolism > A06 - Drugs for constipation > A06A - Drugs for constipation C78272 - Agent Affecting Nervous System > C47794 - Serotonin Agonist D005765 - Gastrointestinal Agents > D054368 - Laxatives Prucalopride is an orally active, selective and specific 5-HT 4 receptor agonist (high affinity), with pKis of 8.6 and 8.1 for human 5-HT4a/4b receptors, respectively. Prucalopride improves intestinal motility by promoting regeneration of the intestinal nervous system in rats. Prucalopride also shows anticancer activity by blocking of the PI3K/AKT/mTor signaling pathway. Prucalopride can be used in studies of chronic constipation, pseudo-intestinal obstruction and cancer[1][2][3].
Pyrazoloacridine
C19H21N5O3 (367.16443160000006)
C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C2842 - DNA Binding Agent D019995 - Laboratory Chemicals > D007202 - Indicators and Reagents > D007364 - Intercalating Agents D000970 - Antineoplastic Agents
(2S)-2-Amino-3-[4-[(2S)-2-amino-3-(1H-indol-3-yl)propanoyl]oxyphenyl]propanoic acid
C20H21N3O4 (367.15319860000005)
4-[[1-(4-Tert-Butylphenyl)-5-oxo-3-pyrrolidinyl]methoxy]benzoic acid
Corynoline
C21H21NO5 (367.14196560000005)
Corynoline is a benzophenanthridine alkaloid that is chelidonine substituted by a methyl group at position 13. Isolated from the aerial parts of Corydalis incisa, it acts as an acetylcholinesterase inhibitor and also exhibits antineoplastic and hepatoprotective activity. It has a role as a metabolite, an EC 3.1.1.7 (acetylcholinesterase) inhibitor, an antineoplastic agent and a hepatoprotective agent. It is a member of isoquinolines, an organic heterohexacyclic compound, a secondary alcohol, a cyclic acetal and a benzophenanthridine alkaloid. It is functionally related to a chelidonine. Corynoline is a natural product found in Corydalis bungeana, Corydalis remota, and other organisms with data available. A benzophenanthridine alkaloid that is chelidonine substituted by a methyl group at position 13. Isolated from the aerial parts of Corydalis incisa, it acts as an acetylcholinesterase inhibitor and also exhibits antineoplastic and hepatoprotective activity. Corynoline is a reversible and noncompetitive acetylcholinesterase (AChE) inhibitor with an IC50 of 30.6 μM[1]. Corynoline exhibits anti-inflammatory activity by activating Nrf2[2]. Corynoline is a reversible and noncompetitive acetylcholinesterase (AChE) inhibitor with an IC50 of 30.6 μM[1]. Corynoline exhibits anti-inflammatory activity by activating Nrf2[2].
N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1h-indole-3-carboxamide
Jacobine N-oxide
A pyrrolizine alkaloid that is jacobine in which the tertiary amino function has been oxidised to the corresponding N-oxide. CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 2257 CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 179 CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 169 CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 159 CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 149 CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 139 CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 129 INTERNAL_ID 129; CONFIDENCE Reference Standard (Level 1) CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 119 CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 109
12-hydroxy-4,19-dimethyl-(13betaH,14betaH)-14,19-dihydro-4,8-seco-crotalanane-8,11,15-trione|8,12-dihydroxy-4alpha,19-dimethyl-11,15-dioxo-(13betaH,14betaH)-14,19-dihydro-crotalananium betaine|Crosemperin|crosemperine
C19H29NO6 (367.19947740000003)
5b,13-dimethyl-5b,6,7,12b,13,14-hexahydro-[1,3]dioxolo[4,5:4,5]benzo[1,2-c][1,3]dioxolo[4,5-i]phenanthridin-6-ol
C21H21NO5 (367.14196560000005)
6-benzoyloxy-2-(hydroxy-phenyl-methyl)-8-methyl-nortropan-3-ol
10b-(2-Methylbut-3-en-2-yl)-3-(2-methylpropyl)-6,10b,11,11a-tetrahydro-2H-pyrazino[1,2:1,5]pyrrolo[2,3-b]indole-1,4(3H,5aH)-dione
(2S,3R)-2-Hydroxy-2-isopropyl-3-tigloyloxy-buttersaeure-((7aR)-(7ar)-hexahydropyrrolizin-1t-ylmethylester)|(2S,3R)-2-hydroxy-2-isopropyl-3-tigloyloxy-butyric acid-((7aR)-(7ar)-hexahydropyrrolizin-1t-ylmethyl ester)
C20H33NO5 (367.23586080000007)
(E)-3-(methylsulfonyl)-propenoic acid 4-(3-methyl-2-butenyloxy)-3-methoxyphenethyl amide|O-methylsakambullin
C18H25NO5S (367.14533600000004)
{2-[5-(4-Aethoxy-3-methoxy-phenyl)-1-phenyl-4,5-dihydro-1H-pyrazol-3-yl]-aethyl}-dimethyl-amin|{2-[5-(4-ethoxy-3-methoxy-phenyl)-1-phenyl-4,5-dihydro-1H-pyrazol-3-yl]-ethyl}-dimethyl-amine
3alpha-(3,4,5-trimethoxybenzoyloxy)tropan-6beta,7beta-diol|3alpha-(3,4,5-trimethoxybenzoyloxy)tropan-6beta,7beta-diol|Tropane-3alpha,6beta,7beta-triol 3-(3,4,5-trimethoxybenzoate)
marmesiline|N-[2-hydroxy-2-[4-[(2-hydroxy-3-methyl-3-butenyl)oxy]phenyl]ethyl]-3-phenyl-(2E)-2-propenamide
1,8-dihydroxy-6-(methyl)-3-methoxy-2-(piperidinium-2-yl) anthraquinone
C21H21NO5 (367.14196560000005)
4-[3-[N-[[(2S,3S)-3-trans-carboxyoxiran-2-yl]carbonyl]-L-leucyl]aminopropanyl]-1H-imidazol-2-ylamine|WF14865B
4-Hydroxycapitavine|trihydroxy-5,7,4 (methyl-1 piperidinyl-2)-6 flavone
C21H21NO5 (367.14196560000005)
Spiro[isoquinoline-1,2-indene],1,2,3,4,2,3-hexahydro-6,7-dimethoxy-2-methyl-6,7-methylendioxy-1-oxo-
C21H21NO5 (367.14196560000005)
Isatidine
Isatidine is a citraconoyl group.
RET-NO
Usaramine N-oxide, a alkaloid isolated from Crotalaria pallida, possesses anti-inflammatory activities[1].
Oxypalmatine
C21H21NO5 (367.14196560000005)
8-Oxypalmatine is a natural product found in Berberis actinacantha, Limaciopsis loangensis, and other organisms with data available. Oxypalmatine is isolated from Phellodendron amurense[1].
Jacobine N-oxide
1,2,9,10-tetramethoxy-6,7-dimethyl-5,6-dihydro-4H-dibenzo[de,g]quinoline
relative retention time with respect to 9-anthracene Carboxylic Acid is 1.137 relative retention time with respect to 9-anthracene Carboxylic Acid is 1.143
Phenoperidine
D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D009294 - Narcotics N - Nervous system > N01 - Anesthetics > N01A - Anesthetics, general > N01AH - Opioid anesthetics D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent D002491 - Central Nervous System Agents > D000700 - Analgesics
N-Acetyl-L-farnesylcysteine
C20H33NO3S (367.2181028000001)
D004791 - Enzyme Inhibitors
N-Acetyl-6-O-L-fucosyl-D-glucosamine
2-Acetamido-2-deoxy-6-O-a-L-fucopyranosyl-D-glucose
-O-Fucopyranosyl-2-acetamido-2-deoxyglucopyranose
Bambuterol
C18H29N3O5 (367.21071040000004)
R - Respiratory system > R03 - Drugs for obstructive airway diseases > R03C - Adrenergics for systemic use > R03CC - Selective beta-2-adrenoreceptor agonists D019141 - Respiratory System Agents > D018927 - Anti-Asthmatic Agents > D001993 - Bronchodilator Agents C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C87053 - Adrenergic Agonist D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents
TRP-Tyr
C20H21N3O4 (367.15319860000005)
A dipeptide formed from L-tryptophan and L-tyrosine residues.
Tyr-TRP
C20H21N3O4 (367.15319860000005)
A dipeptide formed from L-tyrosine and L-tryptophan residues.
Piperundecalidine
Casuarine 6-a-D-glucoside
2-(2H-Benzotriazol-2-yl)-4,6-bis(tert-pentyl)phenol N-oxide
2-(3,4-dimethoxyphenyl)-N-[(2,3-dimethoxyphenyl)methyl]ethanamine,hydrochloride
C19H26ClNO4 (367.15502660000004)
N2-ibu-2-OMe-rG
C15H21N5O6 (367.14917660000003)
N2-Isobutyryl-2'-O-methylguanosine (N2-IBU-2'-OME-RG) is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc[1].
2-(4-N-FMOC-MORPHOLIN-2-YL)ACETIC ACID
C21H21NO5 (367.14196560000005)
Benzenepropanoic acid,a-[(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)oxy]-, 1,1-dimethylethyl ester,(aS)
C21H21NO5 (367.14196560000005)
Dimoxyline
C78281 - Agent Affecting Musculoskeletal System > C29696 - Muscle Relaxant
3-(3-N-BOC-AMINO-PYRROLIDIN-1-YL)-1-(6-CHLORO-PYRIDIN-3-YL)-2-METHYL-PROPAN-1-ONE
1-(6-CHLORO-PYRIDIN-3-YL)-2-METHYL-3-(4-BOC-PIPERAZIN-1-YL)-PROPAN-1-ONE
1-(6-CHLORO-PYRIDIN-3-YL)-3-(4-BOC-PIPERAZIN-1-YL)-BUTAN-1-ONE
(1R,2S,3R,4R,5R)-4-Azido-2,3-bis(benzyloxy)-6,8-dioxabicyclo[3.2. 1]octane (non-preferred name)
C20H21N3O4 (367.15319860000005)
3-METHYL-4-(4-(PYRIDIN-2-YLMETHOXY)CYCLOHEXANECARBOXAMIDO)BENZAMIDE
N-Fmoc-trans-4-hydroxy-L-proline methyl ester
C21H21NO5 (367.14196560000005)
5-(4-(Methylsulfonyl)piperazin-1-yl)pyridine-3-boronic acid pinacol ester
C16H26BN3O4S (367.1736986000001)
N,N-BIS(2-HYDROXYETHYL)-N-METHYLDODECAN-1-AMINIUM BROMIDE
4H,6H-Indeno[2,1-b][1,2,4]triazolo[4,3-d][1,4]oxazinium, 5a,10b-dihydro-2-(2,4,6-trimethylphenyl)-, chloride , (5aS,10bR)
C21H22ClN3O (367.14513120000004)
4-(3-(3-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PHENYL)PROPYL)MORPHOLINE HYDROCHLORIDE
3-[benzyl(propan-2-yl)amino]-1-naphthalen-2-ylpropan-1-one,hydrochloride
C23H26ClNO (367.17028160000007)
(R)-2-Benzyl-3-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl]propanoic acid
N-(1-Boc-piperidin-4-ylidene)-4-methylbenzenesulfonohydrazide
C17H25N3O4S (367.15656900000005)
4-METHYL-3-(4-(PYRIDIN-2-YLMETHOXY)CYCLOHEXANECARBOXAMIDO)BENZAMIDE
Pramiracetam sulfate
C14H29N3O6S (367.17769740000006)
C26170 - Protective Agent > C1509 - Neuroprotective Agent
2-ACETAMIDO-2-DEOXY-3-O-(A-L-FUCOPYRANOSYL)-D-GLUCOPYRANOSE
Methanone, (3-ethyl-5-methyl-4-isoxazolyl)[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]
C18H20F3N3O2 (367.15075360000003)
(S)-N,N-DIMETHYL-8,9,10,11,12,13,14,15-OCTAHYDRODINAPHTHO[2,1-D:1,2-F][1,3,2]DIOXAPHOSPHEPIN-4-AMINE
C22H26NO2P (367.17010660000005)
Tetradecyl 3-amino-4-chlorobenzoate
C21H34ClNO2 (367.22779340000005)
2-[[5-(DIBUTYLAMINO)-2-THIENYL]METHYLENE]-1H-INDENE-1,3(2H)-DIONE
Benzethidine
C78272 - Agent Affecting Nervous System > C67413 - Opioid Receptor Agonist
(S)-2-(((TERT-BUTYLDIMETHYLSILYL)OXY)DIPHENYLMETHYL)PYRROLIDINE
C23H33NOSi (367.23312880000003)
butyl prop-2-enoate,methyl 2-methylprop-2-enoate,2-methylprop-2-enoic acid,prop-2-enenitrile
C19H29NO6 (367.19947740000003)
1,4-divinylbenzene,isocyanatomethylbenzene,styrene
3-(9H-fluoren-9-ylmethoxycarbonylamino)heptanoic acid
2-ACETAMIDO-2-DEOXY-6-O-(ALPHA-L-FUCOPYRANOSYL)-D-GLUCOPYRANOSE
2-Borono-4-(phenylmethoxy)-1H-indole-1-carboxylic acid 1-(1,1-dimethylethyl) ester
N-[(9H-Fluoren-9-ylmethoxy)carbonyl]-2-methyl-L-leucine
Tiracizine
C78274 - Agent Affecting Cardiovascular System > C47793 - Antiarrhythmic Agent D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents C - Cardiovascular system > C01 - Cardiac therapy
S-2-[diphenyl[(triethylsilyl)oxy]Methyl]-Pyrrolidine
C23H33NOSi (367.23312880000003)
ETHYL 2-AMINO-5-((7-ETHOXY-7-OXOHEPTYL)OXY)-4-METHOXYBENZOATE
C19H29NO6 (367.19947740000003)
2,6-Difluoro-3,5-bis(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine
C17H25B2F2NO4 (367.1937654000001)
Benzoicacid, 2-[4-(cyclohexylethylamino)-2-hydroxybenzoyl]-
2-Acetamido-2-deoxy-4-O-(a-L-fucopyranosyl)-D-glucopyranose
Fradafiban
C20H21N3O4 (367.15319860000005)
C78275 - Agent Affecting Blood or Body Fluid > C263 - Anticoagulant Agent
tert-butyl 4-(4-phenylmethoxyphenyl)piperidine-1-carboxylate
Neocitrullamon
C20H21N3O4 (367.15319860000005)
N - Nervous system > N03 - Antiepileptics > N03A - Antiepileptics > N03AB - Hydantoin derivatives
Mirogabalin besylate
C18H25NO5S (367.14533600000004)
C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic
[3H]dehydroepiandrosterone sulfate
COVID info from COVID-19 Disease Map Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
2-(acetylamino)-2-deoxy-3-O-(6-deoxy-alpha-L-galactopyranosyl)-beta-D-glucopyranose
alpha-L-fucosyl-(1->4)-N-acetyl-beta-D-glucosamine
An amino disaccharide consisting of an alpha-L-fucosyl residue attached to N-acetyl-beta-Dglucosamine by a (1->4)-glycosidic linkage.
4-(3,4-Dimethoxyphenyl)-2-(1-piperidinyl)-6-(trifluoromethyl)pyrimidine
C18H20F3N3O2 (367.15075360000003)
N-((2S,3R,4R,5S,6R)-2,4,5-Trihydroxy-6-((((2R,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)methyl)tetrahydro-2H-pyran-3-yl)acetamide
N-((2R,3R,4R,5S,6R)-2,4,5-Trihydroxy-6-((((2R,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)methyl)tetrahydro-2H-pyran-3-yl)acetamide
N-((2S,3R,4R,5S,6R)-2,4-Dihydroxy-6-(hydroxymethyl)-5-(((2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)tetrahydro-2H-pyran-3-yl)acetamide
[N-(2,4-Diaminopteridin-6-YL)-methyl]-dibenz[B,F]azepine
D004791 - Enzyme Inhibitors > D005493 - Folic Acid Antagonists
1-[4-(Aminomethyl)benzoyl]-5-fluoro-1H-spiro[piperidine-4,2-quinazolin]-4-amine
2-[4-(4-Hydroxy-3-isopropyl-phenoxy)-3,5-dimethyl-phenyl]-2H-[1,2,4]triazine-3,5-dione
C20H21N3O4 (367.15319860000005)
prucalopride
D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D017366 - Serotonin Receptor Agonists A - Alimentary tract and metabolism > A06 - Drugs for constipation > A06A - Drugs for constipation C78272 - Agent Affecting Nervous System > C47794 - Serotonin Agonist D005765 - Gastrointestinal Agents > D054368 - Laxatives Prucalopride is an orally active, selective and specific 5-HT 4 receptor agonist (high affinity), with pKis of 8.6 and 8.1 for human 5-HT4a/4b receptors, respectively. Prucalopride improves intestinal motility by promoting regeneration of the intestinal nervous system in rats. Prucalopride also shows anticancer activity by blocking of the PI3K/AKT/mTor signaling pathway. Prucalopride can be used in studies of chronic constipation, pseudo-intestinal obstruction and cancer[1][2][3].
2-amino-N-cyclopentyl-1-(3-methoxypropyl)-1H-pyrrolo[2,3-b]quinoxaline-3-carboxamide
D020536 - Enzyme Activators
16-Methoxytabersoninium(1+)
Conjugate acid of 16-methoxytabersonine arising from protonation of the endocyclic tertiary amino group.
(5Z,9S,11R,13E,15S)-15-hydroperoxy-9,11-epidioxyprosta-5,13-dien-1-oate
3-hydroxy-5-methoxy-6-[(2E)-3-(4-methoxyphenyl)prop-2-enoyl]-2-(3-methylbut-2-en-1-yl)phenolate
(3E)-3-[(2E,4E,6E)-1-hydroxy-8-methyldeca-2,4,6-trienylidene]-5-[(4-hydroxyphenyl)methyl]pyrrolidine-2,4-dione
3-(3-Methyl-5-pentylfuran-2-yl)propanoylcarnitine
C20H33NO5 (367.23586080000007)
(2S)-2-Amino-3-[4-[(2S)-2-amino-3-(1H-indol-3-yl)propanoyl]oxyphenyl]propanoic acid
C20H21N3O4 (367.15319860000005)
Dodeca-6,8,10-trienedioylcarnitine
C19H29NO6 (367.19947740000003)
Dodeca-4,7,10-trienedioylcarnitine
C19H29NO6 (367.19947740000003)
(2E,6E,8E)-Dodeca-2,6,8-trienedioylcarnitine
C19H29NO6 (367.19947740000003)
2-[4-[(2R)-2-[(3S,5S)-3,5-dimethyl-2-oxocyclohexyl]-2-hydroxyethyl]-2,6-dioxo-1-piperidinyl]acetic acid ethyl ester
C19H29NO6 (367.19947740000003)
19-hydroxyprostaglandin H2(1-)
A prostaglandin carboxylic acid anion that is the conjugate base of 19-hydroxyprostaglandin H2, obtained by deprotonation of the carboxy group; major species at pH 7.3.
N-[2-(4-acetyl-1-piperazinyl)phenyl]-2-(2-methylphenoxy)acetamide
2-[(6-methoxy-4-methylquinazolin-2-yl)amino]-6-methyl-5-(3-methylbutyl)pyrimidin-4(3H)-one
N-cyclopentyl-4-(3,4-dimethoxyphenyl)-6-(trifluoromethyl)-2-pyrimidinamine
C18H20F3N3O2 (367.15075360000003)
(2S,3S)-3-{[(2S)-1-{[3-(2-amino-1H-imidazol-4-yl)propyl]amino}-4-methyl-1-oxopentan-2-yl]carbamoyl}oxirane-2-carboxylic acid
2-[4-[2-(1-Cyclohexenyl)ethylsulfamoyl]-2-methylphenoxy]acetic acid methyl ester
C18H25NO5S (367.14533600000004)
N-(1-adamantylmethyl)-2-ethyl-3-methoxy-6-indazolecarboxamide
5-(3-Methylbenzylidene)-2-[(1,7,7-trimethylbicyclo[2.2.1]hept-2-ylidene)hydrazono]-1,3-thiazolidin-4-one
20-hydroxylipoxin A4(1-)
A lipoxin anion that is the conjugate base of 20-hydroxylipoxin A4 arising from deprotonation of the carboxylic acid function; major species at pH 7.3.
20-hydroxylipoxin B4(1-)
A lipoxin anion that is the conjugate base of 20-hydroxy-lipoxin B4 arising from deprotonation of the carboxylic acid function; major species at pH 7.3.
7-(diethylamino)-N-[(4-fluorophenyl)methyl]-2-imino-1-benzopyran-3-carboxamide
(3R,3aS,7R,7aS)-7-methyl-3-(2-naphthalenyl)-2-(phenylmethyl)-3a,6,7,7a-tetrahydro-3H-isoindol-1-one
N-hydroxy-N-[(E)-(4-phenylphenyl)methylideneamino]octanediamide
N-hydroxy-N-[(E)-[4-(2-methylphenyl)phenyl]methylideneamino]heptanediamide
11-dehydro-thromboxane B2(1-)
A thromboxane anion that is the conjugate base of 11-dehydro-thromboxane B2, obtained by deprotonation of the carboxy group; major species at pH 7.3.
(2S,3S)-3-{[(2R)-1-{[3-(2-amino-1H-imidazol-4-yl)propyl]amino}-3-methyl-1-oxopentan-2-yl]carbamoyl}oxirane-2-carboxylic acid
N-[4-[(3-phenylpropanoylamino)carbamoyl]phenyl]pentanamide
1-[1-(Phenylmethyl)-4-piperidinyl]-3-(2-propan-2-ylphenyl)thiourea
C22H29N3S (367.20820740000005)
3-[(4-Ethoxycarbonyl-4-phenyl-1-piperidinyl)methyl]benzoic acid
N-[[3-chloro-4-(1-piperidinyl)anilino]-sulfanylidenemethyl]hexanamide
C18H26ClN3OS (367.14850160000003)
N-[5-ethyl-1-(2-morpholin-4-ylethyl)-2-oxo-3H-indol-3-yl]acetamide;hydrochloride
3-ethoxy-N-[(4-methoxyphenyl)methyl]-2-propyl-6-indazolecarboxamide
[1-(2,1,3-Benzothiadiazol-5-ylmethyl)-4-(2-phenylethyl)-4-piperidinyl]methanol
2-[(2E)-3-(4-hydroxyphenyl)prop-2-enoyl]-3,5-dimethoxy-6-(3-methylbut-2-en-1-yl)phenolate
(5Z,13E,15S)-9alpha,11alpha-epoxy-15,19-dihydroxythromboxa-5,13-dien-1-oate
(5Z,13E,15S)-9alpha,11alpha-epoxy-15,18-dihydroxythromboxa-5,13-dien-1-oate
(5Z,13E,15S)-11alpha,15,19-trihydroxy-6,9alpha-epoxyprosta-5,13-dien-1-oate
(3S)-N-[2-(2,3-dihydro-1,4-benzodioxin-6-ylamino)-2-oxoethyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxamide
C20H21N3O4 (367.15319860000005)
(2S,3S,4S)-2-cyano-3-[4-(2-fluorophenyl)phenyl]-4-(hydroxymethyl)-N-propyl-1-azetidinecarboxamide
(5Z,8S,9E,11Z,13E,15S)-8,15-bis(hydroperoxy)icosa-5,9,11,13-tetraenoate
(5S,6E,8Z,11Z,13E,15S)-5,15-bis(hydroperoxy)icosa-6,8,11,13-tetraenoate
(5Z,8Z,10E,12E,14R,15S)-14,15-bis(hydroperoxy)icosa-5,8,10,12-tetraenoate
(5S,6R,7E,9E,11Z,13E,15S)-15-hydroperoxy-5,6-dihydroxyicosa-7,9,11,13-tetraenoate
Usaramine N-oxide
A pyrrolizine alkaloid that is senecionane bearing two additional hydroxy substituents at positions 12 and 18, two additional oxo groups at positions 11 and 16 and an N-oxido substituent. Usaramine N-oxide, a alkaloid isolated from Crotalaria pallida, possesses anti-inflammatory activities[1].
alpha-L-Rha-(1->3)-beta-D-GlcNAc
An amino disaccharide consisting of N-acetyl-beta-D-glucosamine having an alpha-L-rhamnosyl residue attached at the 3-position.
beta-L-fucosyl-(1->3)-N-acetyl-beta-D-glucosamine
An amino disaccharide consisting of a beta-L-fucosyl residue attached to N-acetyl-beta-Dglucosamine by a (1->3)-glycosidic linkage.
3-[2-(4-methoxyphenyl)-2-[3-(4-methoxyphenyl)propoxy]ethyl]-1H-imidazol-3-ium
4-O-[2-(acetylamino)-2-deoxy-beta-D-glucopyranosyl]-alpha-D-rhamnopyranose
2-O-(2-acetamido-2-deoxy-beta-D-glucopyranosyl)-alpha-L-rhamnopyranose
2-[3-(1-piperidinyl)propoxy]-6H-benzo[b][1]benzothiepin-5-one
(3R,6R,14aR,14bR)-3,6-dihydroxy-3-[(1R)-1-hydroxyethyl]-6-methyl-5-methylidene-3,4,5,6,9,11,13,14,14a,14b-decahydro[1,6]dioxacyclododecino[2,3,4-gh]pyrrolizine-2,7-dione
(2S,3S,4R)-2-cyano-3-[4-(4-fluorophenyl)phenyl]-4-(hydroxymethyl)-N-propan-2-yl-1-azetidinecarboxamide
(2S,3S,4R)-2-cyano-3-[4-(2-fluorophenyl)phenyl]-4-(hydroxymethyl)-N-propyl-1-azetidinecarboxamide
(2S,3S,4S)-2-cyano-3-[4-(4-fluorophenyl)phenyl]-4-(hydroxymethyl)-N-propan-2-ylazetidine-1-carboxamide
(2S,3R,4S)-2-cyano-3-[4-(4-fluorophenyl)phenyl]-4-(hydroxymethyl)-N-propan-2-ylazetidine-1-carboxamide
(2R,3S,4S)-2-cyano-3-[4-(4-fluorophenyl)phenyl]-4-(hydroxymethyl)-N-propan-2-yl-1-azetidinecarboxamide
N-[1-(2,4-difluorophenyl)-4,5,6,7-tetrahydroindazol-4-yl]-2-phenylacetamide
(2R,3R,4S)-2-cyano-3-[4-(2-fluorophenyl)phenyl]-4-(hydroxymethyl)-N-propyl-1-azetidinecarboxamide
(2R,3R,4R)-2-cyano-3-[4-(2-fluorophenyl)phenyl]-4-(hydroxymethyl)-N-propyl-1-azetidinecarboxamide
(2S,3R,4S)-2-cyano-3-[4-(2-fluorophenyl)phenyl]-4-(hydroxymethyl)-N-propyl-1-azetidinecarboxamide
(2S,3R,4R)-2-cyano-3-[4-(2-fluorophenyl)phenyl]-4-(hydroxymethyl)-N-propyl-1-azetidinecarboxamide
(2R,3S,4R)-2-cyano-3-[4-(2-fluorophenyl)phenyl]-4-(hydroxymethyl)-N-propyl-1-azetidinecarboxamide
(2R,3S,4S)-2-cyano-3-[4-(2-fluorophenyl)phenyl]-4-(hydroxymethyl)-N-propyl-1-azetidinecarboxamide
2-(dimethylamino)-1-[(2S,3S)-2-(hydroxymethyl)-1-methylsulfonyl-3-phenyl-1,6-diazaspiro[3.3]heptan-6-yl]ethanone
C17H25N3O4S (367.15656900000005)
(2R,3R,4S)-2-cyano-3-[4-(4-fluorophenyl)phenyl]-4-(hydroxymethyl)-N-propan-2-yl-1-azetidinecarboxamide
(2R,3R,4R)-2-cyano-3-[4-(4-fluorophenyl)phenyl]-4-(hydroxymethyl)-N-propan-2-yl-1-azetidinecarboxamide
(2S,3R,4R)-2-cyano-3-[4-(4-fluorophenyl)phenyl]-4-(hydroxymethyl)-N-propan-2-yl-1-azetidinecarboxamide
(2R,3S,4R)-2-cyano-3-[4-(4-fluorophenyl)phenyl]-4-(hydroxymethyl)-N-propan-2-yl-1-azetidinecarboxamide
(1R,5S)-N-(2-chlorophenyl)-7-[4-[(E)-prop-1-enyl]phenyl]-3,6-diazabicyclo[3.1.1]heptane-6-carboxamide
C21H22ClN3O (367.14513120000004)
2-(dimethylamino)-1-[(2S,3R)-2-(hydroxymethyl)-1-methylsulfonyl-3-phenyl-1,6-diazaspiro[3.3]heptan-6-yl]ethanone
C17H25N3O4S (367.15656900000005)
2-(dimethylamino)-1-[(2R,3R)-2-(hydroxymethyl)-1-methylsulfonyl-3-phenyl-1,6-diazaspiro[3.3]heptan-6-yl]ethanone
C17H25N3O4S (367.15656900000005)
N-hydroxy-N-[(E)-(4-hydroxy-2,6-dimethoxyphenyl)methylideneamino]octanediamide
beta-D-GlcpNAc-(1->3)-alpha-L-Rhap
An amino disaccharide consisting of alpha-L-rhamnose having an N-acetyl beta-D-glucosaminyl residue attached at the 3-position.
N-[9-(2-carboxyethyl)-6-(ethylamino)-2,7-dimethyl-3H-xanthen-3-ylidene]ethanaminium
(13E,15S)-11alpha,15-dihydroxy-6,9-dioxoprost-13-en-1-oate
(5S,6Z,8E,10E,12R,14Z)-5,12,20,20-tetrahydroxyicosa-6,8,10,14-tetraenoate
alpha-(4-Dimethylaminophenyl)-omega-(9-phenanthryl)pentane
2-[[(E)-2-acetamido-3-hydroxyoct-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
Propiverine
G - Genito urinary system and sex hormones > G04 - Urologicals > G04B - Urologicals > G04BD - Drugs for urinary frequency and incontinence C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D010276 - Parasympatholytics D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists C78272 - Agent Affecting Nervous System > C29698 - Antispasmodic Agent D000089162 - Genitourinary Agents > D064804 - Urological Agents
prostaglandin G2(1-)
A prostaglandin carboxylic acid anion that is the conjugate base of prostaglandin G2, obtained by deprotonation of the carboxy group; major species at pH 7.3.
testosterone sulfate(1-)
A steroid sulfate oxoanion that is the conjugate base of testosterone sulfate, obtained by deprotonation of the sulfo group; major species at pH 7.3.
3-O-fucopyranosyl-2-acetamido-2-deoxyglucopyranose
WF14865B
A member of the class of guanidines isolated from the culture mycelium of the fungal strain Aphanoascus fulvescens and has been shown to exhibit inhibitory activity against cathepsin B and L.
WF14865A
A member of the class of guanidines isolated from the culture mycelium of the fungal strain Aphanoascus fulvescens and has been shown to exhibit inhibitory activity against cathepsin B and L.
19-hydroxythromboxane A2(1-)
A thromboxane anion that is the conjugate base of 19-hydroxythromboxane A2, obtained by deprotonation of the carboxy group; major species at pH 7.3.
18-hydroxythromboxane A2(1-)
A thromboxane anion that is the conjugate base of 18-hydroxythromboxane A2, obtained by deprotonation of the carboxy group; major species at pH 7.3.
(5S,15S)-dihydroperoxy-(6E,8Z,11Z,13E)-icosatetraenoate
A bis(hydroperoxy)icosatetraenoate that is the conjugate base of (5S,15S)-dihydroperoxy-(6E,8Z,11Z,13E)-icosatetraenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.
6-oxoprostaglandin E1(1-)
A prostaglandin carboxylic acid anion that is the conjugate base of 6-oxoprostaglandin E1, obtained by deprotonation of the carboxy group; major species at pH 7.3.
8(S),15(S)-DiHPETE(1-)
An icosanoid anion that is the conjugate base of 8(S),15(S)-DiHPETE, obtained by deprotonation of the carboxy group; major species at pH 7.3.
14(R),15(S)-DiHPETE(1-)
A bis(hydroperoxy)icosatetraenoate that is the conjugate base of 14(R),15(S)-DiHPETE, obtained by deprotonation of the carboxy group; major species at pH 7.3.
(5S,6R)-dihydroxy-(15S)-hydroperoxy-(7E,9E,11Z,13E)-icosatetraenoate
An hydroperoxy(hydroxy)icosatetraenoate that is the conjugate base of (5S,6R)-dihydroxy-(15S)-hydroperoxy-(7E,9E,11Z,13E)-icosatetraenoic acid; major species at pH 7.3.
19-hydroxyprostaglandin I2(1-)
A prostaglandin carboxylic acid anion that is the conjugate base of 19-hydroxyprostaglandin I2, obtained by deprotonation of the carboxy group; major species at pH 7.3.
dehydroepiandrosterone sulfate(1-)
The conjugate base of 3beta-hydroxyandrost-5-en-17-one 3-sulfate arising from deprotonation of the sulfate OH group; major species at pH 7.3.
dehydrojacoline
A pyrrolizine alkaloid that is jacoline in which the 5-methyl group has been replaced by methylene.
beta-D-GlcpNAc-(1->2)-alpha-L-Rhap
An amino disaccharide consisting of alpha-L-rhamnose having an N-acetyl beta-D-glucosaminyl residue attached at the 2-position.
beta-D-GlcpNAc-(1->4)-alpha-D-Rhap
An amino disaccharide consisting of an alpha-D-rhamnos residue having an N-acetyl-beta-D-glucosaminyl residue attached at the 4-position.
alpha-L-Fucp-(1->3)-D-GlcpNAc
An amino disaccharide consisting of N-acetyl-D-glucosamine having an alpha-L-fucosyl residue attached at the 3-position.
alpha-L-fucosyl-(1->3)-N-acetyl-beta-D-glucosamine
An amino disaccharide consisting of an alpha-L-fucosyl residue attached to N-acetyl-beta-Dglucosamine by a (1->3)-glycosidic linkage.
LPC(8:1)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
7-ethyl-12-(hydroxymethyl)-5-methyl-7-azapentacyclo[7.6.2.0¹,⁸.0⁵,¹⁶.0¹⁰,¹⁵]heptadecane-3,4,11,12-tetrol
C20H33NO5 (367.23586080000007)
3-[(1-{[3-(2-imino-1,3-dihydroimidazol-4-yl)propyl]-c-hydroxycarbonimidoyl}-3-methylbutyl)-c-hydroxycarbonimidoyl]oxirane-2-carboxylic acid
(2e)-n-[(2r)-2-hydroxy-2-(4-{[(2s)-2-hydroxy-3-methylbut-3-en-1-yl]oxy}phenyl)ethyl]-3-phenylprop-2-enimidic acid
(2s,3s)-3-{[(1s,2s)-1-{[3-(2-imino-1,3-dihydroimidazol-4-yl)propyl]-c-hydroxycarbonimidoyl}-2-methylbutyl]-c-hydroxycarbonimidoyl}oxirane-2-carboxylic acid
8-[(1e)-2,5-dimethylhept-1-en-1-yl]-4-(hydroxymethyl)-7-methyl-9h-carbazole-1,6-diol
n-[(2s,3r,4r,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-2-{[(2s,3r,4s,5r,6r)-4,5,6-trihydroxy-2-methyloxan-3-yl]oxy}oxan-3-yl]ethanimidic acid
(1r,4e,6r,7s,14s,17r)-4-ethylidene-7-hydroxy-7-(hydroxymethyl)-6-methyl-3,8-dioxo-2,9-dioxa-14-azatricyclo[9.5.1.0¹⁴,¹⁷]heptadec-11-en-14-ium-14-olate
n-[(1r,4r,4ar,8as)-4-[(2s,5r)-5-chloro-2,6,6-trimethyloxan-2-yl]-1,6-dimethyl-3,4,4a,7,8,8a-hexahydro-2h-naphthalen-1-yl]carboximidic acid
C21H34ClNO2 (367.22779340000005)
(3s,6s)-3-{[6-(3-methylbut-2-en-1-yl)-1h-indol-3-yl]methyl}-6-(2-methylpropyl)-3,6-dihydropyrazine-2,5-diol
8-[(1e,5s)-2,5-dimethylhept-1-en-1-yl]-4-(hydroxymethyl)-7-methyl-9h-carbazole-1,6-diol
n-[(2r)-2-hydroxy-2-(4-{[(2s)-2-hydroxy-3-methylbut-3-en-1-yl]oxy}phenyl)ethyl]-3-phenylprop-2-enimidic acid
(1s,4s,10s,12r)-12-hydroxy-1-(2-methylbut-3-en-2-yl)-2,8,19-triazapentacyclo[10.7.0.0²,¹⁰.0⁴,⁸.0¹³,¹⁸]nonadeca-13,15,17-triene-3,9-dione
methyl (1r,4s,5s,8r,9s,10s)-5,9-dimethyl-3-oxo-7-azahexacyclo[11.5.1.1⁷,¹⁰.0¹,⁹.0⁴,⁸.0¹⁶,¹⁹]icosa-13(19),16-diene-17-carboxylate
6,13-dimethyl-16-oxo-7-azapentacyclo[10.8.0.0²,⁹.0⁵,⁹.0¹³,¹⁸]icosa-5,14,17-trien-11-yl acetate
6-hydroxy-4,5,6-trimethyl-3,7-dioxo-2,8-dioxa-13-azatricyclo[8.5.1.0¹³,¹⁶]hexadec-10-en-5-yl acetate
2-[(3z)-4,8-dimethylnona-3,7-dien-1-yl]-2-methyl-9h-chromeno[7,8-c]pyrrole-5,7-diol
alistonitrine A
{"Ingredient_id": "HBIN015160","Ingredient_name": "alistonitrine A","Alias": "NA","Ingredient_formula": "C21H25N3O3","Ingredient_Smile": "CC1C2(O1)C3CC4C56C(C3C(=O)OC)(CCN5C2N4C)C7=CC=CC=C7N6","Ingredient_weight": "367.4 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "35060","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "102222299","DrugBank_id": "NA"}
11-hydroxy-2,6,6,10-tetramethyl-15-azapentacyclo[11.6.1.0²,¹¹.0⁵,¹⁰.0¹⁶,²⁰]icosa-1(19),13,16(20)-triene-17,18-dione
(2s,3s)-3-{[(1s)-1-{[3-(2-imino-1,3-dihydroimidazol-4-yl)propyl]-c-hydroxycarbonimidoyl}-3-methylbutyl]-c-hydroxycarbonimidoyl}oxirane-2-carboxylic acid
7-hydroxy-2-[hydroxy(phenyl)methyl]-8-methyl-8-azabicyclo[3.2.1]octan-3-yl benzoate
11-(2h-1,3-benzodioxol-5-yl)-1-(piperidin-1-yl)undeca-2,4,10-trien-1-one
(2e)-n-[(1s,2s,4s,5s,6s,7r,8s)-1,5,7-trihydroxy-10-oxo-3-oxatricyclo[4.3.1.0²,⁴]decan-8-yl]dec-2-enimidic acid
C19H29NO6 (367.19947740000003)
1-[2-(2h-1,3-benzodioxol-5-yl)-1,2,4a,5,6,7,8,8a-octahydronaphthalene-1-carbonyl]piperidine
methyl (1r,2s,3r,5r,10s)-2,6-dimethyl-20-oxo-8-azahexacyclo[11.5.1.1¹,⁵.0²,¹⁰.0³,⁸.0¹⁶,¹⁹]icosa-13(19),16-diene-17-carboxylate
(1s,2s,9r,11r,12s,13r)-6,13-dimethyl-16-oxo-7-azapentacyclo[10.8.0.0²,⁹.0⁵,⁹.0¹³,¹⁸]icosa-5,14,17-trien-11-yl acetate
2-(6-aminopurin-9-yl)-5-({[3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy}methyl)oxolan-3-ol
C15H21N5O6 (367.14917660000003)
(1s,4r,7s,9r)-6-hydroxy-9-(2-methylbut-3-en-2-yl)-4-(2-methylpropyl)-2,5,16-triazatetracyclo[7.7.0.0²,⁷.0¹⁰,¹⁵]hexadeca-5,10,12,14-tetraen-3-one
(6r,6as,8s,10r,10as)-6-ethyl-4-(4-hydroxyphenyl)-6a,8,10-trimethyl-6h,7h,8h,9h,10h,10ah-isochromeno[4,3-c]pyridin-1-ol
(1s,2s,4ar,5s,8ar)-2-hydroxy-5-(1h-indol-3-ylmethyl)-1,4a-dimethyl-6-methylidene-hexahydro-2h-naphthalene-1-carboxylic acid
5-({2-imino-5-[(4-methoxyphenyl)methyl]-1,3-dimethylimidazol-4-yl}methyl)-2-methoxyphenol
(1s,2r,3s,5s,7r)-7-hydroxy-2-[(s)-hydroxy(phenyl)methyl]-8-methyl-8-azabicyclo[3.2.1]octan-3-yl benzoate
3-{[5-(3-methylbut-2-en-1-yl)-1h-indol-3-yl]methyl}-6-(2-methylpropyl)-3,6-dihydropyrazine-2,5-diol
(3s,6s)-3-{[5-(3-methylbut-2-en-1-yl)-1h-indol-3-yl]methyl}-6-(2-methylpropyl)-3,6-dihydropyrazine-2,5-diol
(3z,9r,10r,11z,13e,15e,17z,19z,21s)-7,21-dimethyl-1-azacyclodocosa-1,3,5,7,11,13,15,17,19-nonaene-2,9,10-triol
(1r,2r,3r,5r,7s)-7-hydroxy-2-[(r)-hydroxy(phenyl)methyl]-8-methyl-8-azabicyclo[3.2.1]octan-3-yl benzoate
6-ethyl-4-(4-hydroxyphenyl)-6a,8,10-trimethyl-6h,7h,8h,9h,10h,10ah-isochromeno[4,3-c]pyridin-1-ol
(3s,8as)-1-hydroxy-3-{[6-hydroxy-2-(3-methylbut-2-en-1-yl)-1h-indol-3-yl]methyl}-3h,6h,7h,8h,8ah-pyrrolo[1,2-a]pyrazin-4-one
n-[(1r,4r,4ar,8as)-4-[(2s,5s)-5-chloro-2,6,6-trimethyloxan-2-yl]-1,6-dimethyl-3,4,4a,7,8,8a-hexahydro-2h-naphthalen-1-yl]carboximidic acid
C21H34ClNO2 (367.22779340000005)
n-[4-(5-chloro-2,6,6-trimethyloxan-2-yl)-1,6-dimethyl-3,4,4a,7,8,8a-hexahydro-2h-naphthalen-1-yl]carboximidic acid
C21H34ClNO2 (367.22779340000005)
2-(4,8-dimethylnona-3,7-dien-1-yl)-2-methyl-9h-chromeno[7,8-c]pyrrole-5,7-diol
6-hydroxy-4-isopropyl-5,6,13-trimethyl-2,8-dioxa-13-azabicyclo[8.5.1]hexadec-10-ene-3,7,16-trione
C19H29NO6 (367.19947740000003)
(2r,3r,5s)-2-(6-aminopurin-9-yl)-5-({[(2r,3r,5s)-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy}methyl)oxolan-3-ol
C15H21N5O6 (367.14917660000003)
(1r,4r,5r,6r,16r)-6-hydroxy-4,5,6-trimethyl-3,7-dioxo-2,8-dioxa-13-azatricyclo[8.5.1.0¹³,¹⁶]hexadec-10-en-5-yl acetate
3-hydroxy-2-[hydroxy(phenyl)methyl]-8-methyl-8-azabicyclo[3.2.1]octan-6-yl benzoate
(2s,4e)-4-[(2z)-2-{[(1s)-4-carbamimidamido-1-carboxybutyl]imino}ethylidene]-2,3-dihydro-1h-pyridine-2,6-dicarboxylic acid
C15H21N5O6 (367.14917660000003)
7-hydroxy-3',6,7-trimethyl-2,9-dioxa-14-azaspiro[bicyclo[9.5.1]heptadecane-4,2'-oxiran]-11-ene-3,8,17-trione
(1r,4e,6r,7s)-4-ethylidene-7-hydroxy-7-(hydroxymethyl)-6-methyl-3,8-dioxo-2,9-dioxa-14-azatricyclo[9.5.1.0¹⁴,¹⁷]heptadec-11-en-14-ium-14-olate
6-hydroxy-9-(2-methylbut-3-en-2-yl)-4-(2-methylpropyl)-2,5,16-triazatetracyclo[7.7.0.0²,⁷.0¹⁰,¹⁵]hexadeca-5,10,12,14-tetraen-3-one
(1r,2r,4s,8s,10r,11r,13s,15r)-11-hydroxy-15-methyl-6-azapentacyclo[8.6.0.0¹,⁶.0²,¹³.0⁴,¹⁰]hexadecan-8-yl benzoate
n-[4,5-dihydroxy-6-(hydroxymethyl)-2-[(4,5,6-trihydroxy-2-methyloxan-3-yl)oxy]oxan-3-yl]ethanimidic acid
(3z,9s,10r,11z,13e,15e,17z,19z,21s)-7,21-dimethyl-1-azacyclodocosa-1,3,5,7,11,13,15,17,19-nonaene-2,9,10-triol
9,10-dihydroxy-7,21-dimethyl-1-azacyclodocosa-3,5,7,11,13,15,17,19-octaen-2-one
1-hydroxy-3-{[6-hydroxy-2-(3-methylbut-2-en-1-yl)-1h-indol-3-yl]methyl}-3h,6h,7h,8h,8ah-pyrrolo[1,2-a]pyrazin-4-one
(12s,16s,17r,19r,20s)-22-hydroxy-16,20-dimethyl-4-oxa-14-azahexacyclo[15.4.1.0²,⁷.0⁸,²¹.0¹²,²⁰.0¹⁴,¹⁹]docosa-1(22),2(7),8(21)-triene-3,9-dione
6-hydroxy-9-(2-methylbut-3-en-2-yl)-4-(sec-butyl)-2,5,16-triazatetracyclo[7.7.0.0²,⁷.0¹⁰,¹⁵]hexadeca-5,10,12,14-tetraen-3-one
n-[(1r,4r,4ar,8ar)-4-[(2s,5r)-5-chloro-2,6,6-trimethyloxan-2-yl]-1,6-dimethyl-3,4,4a,7,8,8a-hexahydro-2h-naphthalen-1-yl]carboximidic acid
C21H34ClNO2 (367.22779340000005)
(2s,5s,10s,11s)-11-hydroxy-2,6,6,10-tetramethyl-15-azapentacyclo[11.6.1.0²,¹¹.0⁵,¹⁰.0¹⁶,²⁰]icosa-1(19),13,16(20)-triene-17,18-dione
(1s,4r,7s,9r)-4-[(2r)-butan-2-yl]-6-hydroxy-9-(2-methylbut-3-en-2-yl)-2,5,16-triazatetracyclo[7.7.0.0²,⁷.0¹⁰,¹⁵]hexadeca-5,10,12,14-tetraen-3-one
3-[(1-{[3-(2-imino-1,3-dihydroimidazol-4-yl)propyl]-c-hydroxycarbonimidoyl}-2-methylbutyl)-c-hydroxycarbonimidoyl]oxirane-2-carboxylic acid
(2e)-n-[(1s,2s,4s,5r,6s,7s,8s)-1,5,7-trihydroxy-10-oxo-3-oxatricyclo[4.3.1.0²,⁴]decan-8-yl]dec-2-enimidic acid
C19H29NO6 (367.19947740000003)
(1r,4z,6r,7s,14s,17r)-4-ethylidene-7-hydroxy-7-(hydroxymethyl)-6-methyl-3,8-dioxo-2,9-dioxa-14-azatricyclo[9.5.1.0¹⁴,¹⁷]heptadec-11-en-14-ium-14-olate
3-methanesulfonyl-n-(2-{3-methoxy-4-[(3-methylbut-2-en-1-yl)oxy]phenyl}ethyl)prop-2-enimidic acid
C18H25NO5S (367.14533600000004)
2-(4,8-dimethylnona-3,7-dien-1-yl)-2-methyl-6h-chromeno[6,7-c]pyrrole-5,8-diol
(1s,2r,3r,5s,6s)-3-hydroxy-2-[(s)-hydroxy(phenyl)methyl]-8-methyl-8-azabicyclo[3.2.1]octan-6-yl benzoate
2,6,12-trihydroxy-10-(3-hydroxybutan-2-yl)-5-(1-hydroxyethyl)-4,11-dimethyl-7-oxa-4-azatricyclo[6.4.0.0²,⁶]dodeca-1(12),8,10-trien-3-one
(1r,3's,4s,6r,7r,11z)-7-hydroxy-3',6,7-trimethyl-2,9-dioxa-14-azaspiro[bicyclo[9.5.1]heptadecane-4,2'-oxiran]-11-ene-3,8,17-trione
22-hydroxy-16,20-dimethyl-4-oxa-14-azahexacyclo[15.4.1.0²,⁷.0⁸,²¹.0¹²,²⁰.0¹⁴,¹⁹]docosa-1(22),2(7),8(21)-triene-3,9-dione
(1s,4r,7s,9r)-4-[(2s)-butan-2-yl]-6-hydroxy-9-(2-methylbut-3-en-2-yl)-2,5,16-triazatetracyclo[7.7.0.0²,⁷.0¹⁰,¹⁵]hexadeca-5,10,12,14-tetraen-3-one
(1r,4z,7s,17r)-4-ethylidene-7-hydroxy-7-(hydroxymethyl)-6-methyl-3,8-dioxo-2,9-dioxa-14-azatricyclo[9.5.1.0¹⁴,¹⁷]heptadec-11-en-14-ium-14-olate
n-{1,5,7-trihydroxy-10-oxo-3-oxatricyclo[4.3.1.0²,⁴]decan-8-yl}dec-2-enimidic acid
C19H29NO6 (367.19947740000003)
2-[(3z)-4,8-dimethylnona-3,7-dien-1-yl]-2-methyl-6h-chromeno[6,7-c]pyrrole-5,8-diol
1-[(1s,2s,4ar,8ar)-2-(2h-1,3-benzodioxol-5-yl)-1,2,4a,5,6,7,8,8a-octahydronaphthalene-1-carbonyl]piperidine
(1r,4r,5s,6r,10z)-6-hydroxy-4-isopropyl-5,6,13-trimethyl-2,8-dioxa-13-azabicyclo[8.5.1]hexadec-10-ene-3,7,16-trione
C19H29NO6 (367.19947740000003)
8-(2,5-dimethylhept-1-en-1-yl)-4-(hydroxymethyl)-7-methyl-9h-carbazole-1,6-diol
(2e)-3-methanesulfonyl-n-(2-{3-methoxy-4-[(3-methylbut-2-en-1-yl)oxy]phenyl}ethyl)prop-2-enimidic acid
C18H25NO5S (367.14533600000004)
(1s,4s,7s,9r)-6-hydroxy-9-(2-methylbut-3-en-2-yl)-4-(2-methylpropyl)-2,5,16-triazatetracyclo[7.7.0.0²,⁷.0¹⁰,¹⁵]hexadeca-5,10,12,14-tetraen-3-one
4,5,15,16-tetramethoxy-8,10-dimethyl-10-azatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadeca-1(17),2(7),3,5,8,13,15-heptaene
n-[(1s,2s,4s,5r,6s,7s,8s)-1,5,7-trihydroxy-10-oxo-3-oxatricyclo[4.3.1.0²,⁴]decan-8-yl]dec-2-enimidic acid
C19H29NO6 (367.19947740000003)